November 26, 2018 04:19 PM ESTUpdated November 27, 06:56 AM

Vivek Ramaswamy ramps up biotech startup #14 — this time working on a gene therapy for sickle cell disease and β-thalassemia

John Carroll

Editor & Founder

Vivek Ramaswamy’s Roivant Sciences has nabbed its latest clinical-stage program for biotech startup #14 — Aruvant — and this time they’re going up against a couple of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vivek Ramaswamy ramps up biotech startup #14 — this time working on a gene therapy for sickle cell disease and β-thalassemia

John Carroll

Editor & Founder

Sign up to read this article for free.

Doses of Lilly's blockbuster GLP-1 in shortage have been pulled from FDA supply list

PARP biotech backed by more than five pharmas closes after nine years

23andMe board rejects Anne Wojcicki’s take-private plan, requests changes

Massachusetts' plan for $1B in life science investment stalls in state legislature

Iron chelator therapy unexpectedly worsened Alzheimer’s disease in clinical study

Hybrid Clinical Trials: Changing the dynamic and building a more efficient trial ecosystem.

Vivek Ra­maswamy ramps up biotech start­up #14 — this time work­ing on a gene ther­a­py for sick­le cell dis­ease and β-tha­lassemia

John Carroll

Editor & Founder

Sign up to read this article for free.

Dos­es of Lil­ly's block­buster GLP-1 in short­age have been pulled from FDA sup­ply list

PARP biotech backed by more than five phar­mas clos­es af­ter nine years

23andMe board re­jects Anne Wo­j­ci­c­ki’s take-pri­vate plan, re­quests changes

Mass­a­chu­setts' plan for $1B in life sci­ence in­vest­ment stalls in state leg­is­la­ture

Iron chela­tor ther­a­py un­ex­pect­ed­ly wors­ened Alzheimer’s dis­ease in clin­i­cal study

Hy­brid Clin­i­cal Tri­als: Chang­ing the dy­nam­ic and build­ing a more ef­fi­cient tri­al ecosys­tem.

Vivek Ramaswamy ramps up biotech startup #14 — this time working on a gene therapy for sickle cell disease and β-thalassemia

Doses of Lilly's blockbuster GLP-1 in shortage have been pulled from FDA supply list

PARP biotech backed by more than five pharmas closes after nine years

23andMe board rejects Anne Wojcicki’s take-private plan, requests changes

Massachusetts' plan for $1B in life science investment stalls in state legislature

Iron chelator therapy unexpectedly worsened Alzheimer’s disease in clinical study

Hybrid Clinical Trials: Changing the dynamic and building a more efficient trial ecosystem.